Eli Lilly and (LLY) Given a $100.00 Price Target at Jefferies Group
Eli Lilly and (NYSE:LLY) has been assigned a $100.00 price objective by Jefferies Group in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price suggests a potential upside of 14.97% from the company’s current price.
A number of other research firms also recently commented on LLY. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the company from $86.98 to $95.00 in a report on Tuesday. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the company from $85.52 to $115.00 in a report on Friday, January 5th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $92.75.
Shares of Eli Lilly and (NYSE:LLY) opened at $86.98 on Tuesday. The company has a market capitalization of $95,770.00, a PE ratio of 41.42, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and has a fifty-two week low of $74.00 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 earnings per share. equities analysts expect that Eli Lilly and will post 4.22 EPS for the current fiscal year.
In other news, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the transaction, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 251,088 shares of company stock valued at $22,041,236. Insiders own 0.20% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ronna Sue Cohen raised its stake in Eli Lilly and by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock valued at $218,000 after buying an additional 9 shares during the period. Tarbox Group Inc. increased its stake in shares of Eli Lilly and by 0.7% during the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after purchasing an additional 11 shares during the period. Accredited Investors Inc. increased its stake in shares of Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after purchasing an additional 14 shares during the period. Private Trust Co. NA increased its stake in shares of Eli Lilly and by 0.3% during the first quarter. Private Trust Co. NA now owns 5,384 shares of the company’s stock worth $387,000 after purchasing an additional 16 shares during the period. Finally, MCF Advisors LLC increased its stake in shares of Eli Lilly and by 0.4% during the first quarter. MCF Advisors LLC now owns 3,918 shares of the company’s stock worth $282,000 after purchasing an additional 17 shares during the period. Institutional investors and hedge funds own 76.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/16/eli-lilly-and-lly-given-a-100-00-price-target-at-jefferies-group.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.